
Brand Name | Status | Last Update |
|---|---|---|
| adreview | New Drug Application | 2024-01-10 |
Expiration | Code | ||
|---|---|---|---|
IOBENGUANE I-131, AZEDRA, PROGENICS PHARMS INC | |||
| 2025-07-30 | ODE-204 | ||

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pheochromocytoma | D010673 | — | — | 1 | 1 | — | — | — | 1 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | 1 | — | — | — | 1 |
| Paraganglioma | D010235 | — | — | 1 | 1 | — | — | — | 1 |
| Drug common name | Iobenguane i 131 |
| INN | iobenguane (131i) |
| Description | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. |
| Classification | Small molecule |
| Drug class | iodine-containing contrast media |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)NCc1cccc([131I])c1 |
| PDB | — |
| CAS-ID | 77679-27-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1615779 |
| ChEBI ID | — |
| PubChem CID | 60860 |
| DrugBank | DB06704 |
| UNII ID | Q461L7AK4R (ChemIDplus, GSRS) |

